Cerevance is a series b startup based in United States. 1 investor tracked.
Cerevance is a startup founded in 2017 based in the Netherlands. Its most recent tracked round is Series-c-plus. Brouky records 2 investors associated with the company.
Cerevance is a clinical-stage biopharmaceutical company focused on advancing cell type-specific therapies for neurodegenerative diseases and obesity, utilizing its proprietary NETSseq platform to identify novel therapeutic targets from human brain tissue samples.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.